Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 8,845 shares at $0.70 ($6K) on 2019-01-10, disclosed to the SEC on 2019-01-11.
Open-market purchase of $6k OTLK by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.73 | 2,792 | $2K | 32.5% |
| 2 | $0.70 | 6,053 | $4K | 67.5% |
| Total | $0.71 avg | 8,845 | $6K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |